熊本大学大学院生命科学研究部 消化器内科学分野

  • ご挨拶
  • お知らせ
    お知らせ一覧
    教室行事
    臨床研究について(オプトアウト)
  • 患者様へ
    外来のご案内
    診療案内
    入院病棟について
    画像検査
    消化器の病気Q&A
    Fib-4index計算サイト
    飲酒習慣スクリーニングテスト
  • 医療従事者の方々へ
    スタッフ紹介
    研究・業績
    診療案内
    学術奨励賞
  • 学生・研修医の皆様へ
    医局見学について
    後期研修・入局のお申込み
  • 消化器内科について
    リンク
    アクセス
  • お問い合わせ

Research & achievements研究・業績aaa

Research paper

Category
  • 研究活動

  • 研究論文和文

  • 研究論文英文

  • 学会発表

  • 主催講演会

2018年度

  • 2018年度

    Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

    Surgery today 48(4) 431-438 2018

    Takeyama H, Beppu T, Higashi T, Kaida T, Arima K, Taki K, Imai K, Nitta H, Hayashi H, Nakagawa S, Okabe H, Hashimoto D, Chikamoto A, Ishiko T, Tanaka M, Sasaki Y, Baba H.
    Vonoprazan is superior to rabeprazole for healing endoscopic submucosal dissection induced ulcers.

    Digestion 97:170-176, 2018

    Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y and Fujisaki J.
    The Incidence of Complications in Single-stage Endoscopic Stone Removal for Patients with Common Bile Duct Stones: A Propensity Score Analysis.

    Intern Med. 2018; 57(4): 469-477

    Saito H, Kadono Y, Kamikawa K, Urata A, Imamura H, Matsushita I, Kakuma T, Tada S.
    Usefullness and limitations of dual-layer spectral detector computed tomography for diagnosing biliary stones not detected by conventional computed tomography: a report of three cases.

    Clin J Gastroenterol. 2018; 11(2): 172-177

    Saito H, Noda K, Ogasawara K, Atsuji S, Takaoka H, Kajihara H, Nasu J, Morishita S, Matsushita I, Katahira K.
    Reduced iodinated contrast media for abdominal imaging by dual-layer spectral detector computed tomography for patients with kidney disease.

    Radiol Case Rep. 2018 13(2): 437-443

    Saito H, Noda K, Ogasawara K, Atsuji S, Takaoka H, Kajihara H, Nasu J, Kitaoka M, Morishita S, Matsushita I, Katahira K.
    Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The lancet.

    Gastroenterology & hepatology 3(6) 424-432 2018

    Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y, SILIUS study group.
    Analysis for the primary predictive factor for the incidence of esophageal injury after ablation of atrial fibrillation.

    J Cardiol. 2018 Dec;72(6):480-487.

    Ito M, Yamabe H, Koyama J, Kanazawa H, Kaneko S, Kanemaru Y, Kiyama T, Arima Y, Takashio S, Yamamoto E, Izumiya Y, Kojima S, Kaikita K, Shono T, Utsunomiya D, Sasaki Y, Yamashita Y, Tsujita K.
    Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.

    Drug Deliv. 2018 Nov;25(1):1067-1077.

    Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T.
    Spleen Dose-Volume Parameters as a Predictor of Treatment-related Lymphopenia During Definitive Chemoradiotherapy for Esophageal Cancer.

    In Vivo. 2018 Nov-Dec;32(6):1519-1525.

    Saito T, Toya R, Yoshida N, Shono T, Matsuyama T, Ninomura S, Watakabe T, Sasaki Y, Baba H, Oya N.
    Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.

    Oncol Lett. 2018 Oct;16(4):5275-5281.

    Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H.
    Impact of retroflexion in the right colon after repeated forward-view examination.

    JGH Open. 2018 Sep 10;2(6):282-287.

    Miyamoto H, Naoe H, Oda Y, Shono T, Narita R, Oyama S, Hashigo S, Okuda A, Hasuda K, Tanaka M, Sakurai K, Murakami Y, Sasaki Y.
    Aspartate beta-hydroxylase promotes cholangiocarcinoma progression by modulating RB1 phosphorylation.

    Cancer Lett. 2018 Aug 10; 429:1-10.

    Huang CK,Iwagami Y,Aou J,Casulli S,Lu S,Nagaoka K,Ji C,Ogawa K,Cao KY,Gao JS,Carlson RI,Wandas JR.
    Usefulness of Virtual Touch Quantification for Staging Liver Fibrosis in Patients with Hepatitis C, and Factors Affecting Liver Stiffness Measurement Failure Compared with Liver Biopsy.

    Hepatol Res. Apr; 48(5):373-382, 2018

    Tsukano N, Miyase S, Saeki T, Mizobe K, Iwashita H, Arima N, Fujiyama S.
    Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomized, open label, phase 3 trial.

    The Lancet Gastroenterology Hepatology. 2018 Jun; 3(6): 424-432

    Kudo M, Ueshima K, Yokosuka O, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura K, Arai Y, the SILIUS study group.
    LSD1 mediates metabolic reprogramming by glucocorticoids during myogenic differentiation.

    Nucleic Acids Res. 2018 Jun 20; 46(11):5441-5454.

    Anan K, Hino S, Shimizu N, Sakamoto A, Nagaoka K, Takase R, Kohrogi K, Araki H, Hino Y, Usuki S, Oki S, Tanaka H, Nakamura K, Endo F, Nakao M.
    Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.

    CPT Pharmacometrics Syst Pharmacol. 2018 Jun;7(6):384-393.

    Oniki K, Watanabe T, Kudo M, Izuka T, Ono T, Matsuda K, Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y, Watanabe H, Maruyama T, Otake K, Ogata Y, Saruwatari J.
    Impact of retroflexion in the right colon after repeated forward-view examinations.

    JGH open 2/P.282-287/2018

    Miyamoto H, Naoe H, Oda Y, Shono T, Narita R, Oyama S, Hashigo S, Okuda A, Hasuda K, Tanaka M, Sakurai K, Murakami Y, Sasaki Y
    Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver

    Transplant Proc 50/P.3858-3862/2018

    Harimoto N, Nakagawara H, Shirabe K, Yoshizumi T, Itoh S, Ikegami T, Soejima Y, Maehara Y, Ishida Y, Tateno C, Tanaka Y
    Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C.

    Open Forum Infect Dis 5/P.ofy268-/2018

    Matsuura K, Aizawa N, Enomoto H, Nishiguchi S, Toyoda H, Kumada T, Iio E, Ito K, Ogawa S, Isogawa M, Alter HJ, Tanaka Y.
    Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B

    Aliment Pharmacol Ther 48/P.1128-1137/2018

    Hsu Y-C, Jun T, Huang Y-T, Yeh M-L, Lee C-L, Ogawa S, Cho S-H, Lin J-T, Yu M-L, Nguyen MH, Tanaka Y
    Increased EZH2 expression during the adenoma-carcinoma sequence in colorectal cancer.

    Oncol Lett 16/P.5275-5281/2018

    Ohuchi M, Sakamoto Y, Tokunaga R, Kiyozumi Y, Nakamura K, Izumi D, Kosumi K, Harada K, Kurashige J, Iwatsuki M, Baba Y, Miyamoto Y, Yoshida N, Shono T, Naoe H, Sasaki Y, Baba H.
    Type I interferon signaling prevents hepatitis B virus-specific T cell responses by reducing antigen expression

    J Virol 92/P.e01099-/2018

    Kawashima K, Isogawa M, Hamada-Tsutsumi S, Baudi I, Saito S, Nakajima A, Tanaka Y
    Intrahepatic Cross-Presentation and Hepatocellular Antigen Presentation Play Distinct Roles in the Induction of Hepatitis B Virus-Specific CD8 + T Cell Responses

    J Virol 92/P.e00920-/2018

    Murata Y, Kawashima K, Sheikh K, Tanaka Y, Isogawa M
    Screening of microRNAs for a repressor of hepatitis B virus replication

    Oncotarget 9/P.29857-29868/2018

    Naito Y, Hamada-Tsutsumi S, Yamamoto Y, Kogure A, Yoshioka Y, Watashi K, Ochiya T, Tanaka Y
    Sofosbuvir–velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals

    Hepatol Int 12/P.356-367/2018

    Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M
    Dysregulation of miRNA in chronic hepatitis B is associated with hepatocellular carcinoma risk after nucleos(t)ide analogue treatment.

    Cancer Lett 434/P.91-100/2018

    Wakasugi H, Takahashi H, Niinuma T, Kitajima H, Oikawa R, Matsumoto N, Takeba Y, Otsubo T, Takagi M, Ariizumi Y, Suzuki M, Okuse C, Iwabuchi S, Nakano M, Akutsu N, Kang J-H, Matsui T, Yamada N, Sasaki H, Yamamoto E, Kai M, Sasaki Y, Sasaki S, Tanaka Y, Yotsuyanagi H, Tsutsumi T, Yamamoto H, Tokino T, Nakase H, Suzuki H, Itoh F
    Clinical evaluation of a novel and highly sensitive immunoassay for anti-hepatitis B core antigen using a fully automated immunochemical analyzer

    Hepatol Res 48/P.1081-1091/2018

    Izumida K, Kaneko A, Takahashi K, Kusumoto S, Narita T, Takami A, Iida S, Aoyagi K, Tanaka Y
    Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infection

    Hepatol Res 48/P.1172-1177/2018

    Tajiri H, Takano T, Tanaka Y, Murakami J, Brooks S
    De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry

    Cell Chem Biol 25/P.906-915. e7/2018

    Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T
    Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells

    Mol Ther 26/P.1840-1854/2018

    Gailhouste L, Liew LC, Yasukawa K, Hatada I, Tanaka Y, Nakagama H, Ochiya T
    Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan

    J Gastroenterol 53/P.1276-1284/2018

    Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein level as a diagnostic marker of hepatitis B virus-related hepatocellular carcinoma

    Hepatol Res 48/P.872-881/2018

    Chuaypen N, Chittmittraprap S, Pinjaroen N, Sirichindakul B, Poovorawan Y, Tanaka Y, Tangkijvanich P
    Gut dysbiosis associated with hepatitis C virus infection

    Clin Infect Dis 67/P.869-877/2018

    Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M, Yoshiji H, Tanaka Y
    Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment

    Hepatol Int 12/P.133-142/2018

    Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K
    Modeling of the Weight Status and Risk of Nonalcoholic Fatty Liver Disease in Elderly Individuals: The Potential Impact of the Disulfide Bond-Forming Oxidoreductase A-Like Protein (DsbA-L) Polymorphism on the Weight Status.

    CPT Pharmacometrics Syst Pharmacol 7/P.384-393/2018

    Oniki K, Watanabe T, Kudo M,Izuka T, Ono T, Matsuda K,Sakamoto Y, Nagaoka K, Imafuku T, Ishima Y,Watanabe H, Maruyama T, Otake K,Ogata Y, Saruwatari J
    Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease

    Hepatol Res 48/P.549-555/2018

    Arai T, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K
    Vonoprazan is Superior to Rabeprazole for Healing Endoscopic Submucosal Dissection: Induced Ulcers

    Digestion 97/P.170-176/2018

    Yamasaki A, Yoshio T, Muramatsu Y, Horiuchi Y, Ishiyama A, Hirasawa T, Tsuchida T, Sasaki Y, Fujisaki J
    High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues

    J Gastroenterol 53/P.883-889/2018

    Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y
    Antiviral therapy for hepatitis B virus during second pregnancies

    J Obstet Gynaecol Res 44/P.566-569/2018

    Wakano Y, Sugiura T, Endo T, Ito K, Suzuki M, Tajiri H, Tanaka Y, Saitoh S
    Late relapse after a sustained virologic response at 24 weeks after treatment with daclatasvir and asunaprevir combination therapy for chronic hepatitis c virus genotype 1b infection with liver cirrhosis

    Intern Med 57/P.951-956/2018

    Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W
    Changes in serum lipid profiles caused by three regimens of interferon-free direct-acting antivirals for patients infected with hepatitis C virus

    Hepatol Res 48/P.E203-E212/2018

    Inoue T, Goto T, Iio E, Matsunami K, Fujiwara K, Shinkai N, Matsuura K, Matsui T, Nojiri S, Tanaka Y
    Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon–based therapy

    Clin Microbiol Infect 24/P.306. e7-306. e13/2018

    Chuaypen N, Posuwan N, Chittmittraprap S, Hirankarn N, Treeprasertsuk S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P
    Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease

    J Gastroenterol 53/P.438-448/2018

    Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, Hara T, Umemura A, Nishikawa T, Moriguchi M, Yasui K, Kamaguchi M, Nishioji K, Mochizuki N, Kobayashi M, Mori K, Tanaka S, Matsuura K, Tanaka Y, Itoh Y
    Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy.

    J Gastroenterol 53/P.247-257/2018

    Matsumoto A, Nishiguchi S, Enomoto H, Kang J-H, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E
    Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan

    J Gastroenterol 53/P.119-128/2018

    Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N
    Effect of hepatitis B virus subgenotype on antiviral response in nucleoside-treated hepatitis B envelope antigen-positive patients

    Hepatol Res 48/P.134-143/2018

    Shen S, Liang X, Hamed K, Tanaka Y, Omagari K, Fan R, Xie Q, Tan D, Zhou B, Jia J-D, Hou J, Sun J
  • Greetingご挨拶
  • OPT OUT臨床研究について(オプトアウト)
  • Newsお知らせ
  • Event教室行事
  • Linkリンク
  • Accessアクセス
ⓒ Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University